What bodily systems are involved in sapropterin's phenylalanine control?

What systems does sapropterin act on to lower phenylalanine?

Sapropterin is a synthetic form of tetrahydrobiopterin (BH4), the natural cofactor required by phenylalanine hydroxylase (PAH) to convert phenylalanine into tyrosine. By increasing BH4 availability, sapropterin improves PAH activity in patients who still retain some residual enzyme function, thereby lowering blood phenylalanine levels.

Why does sapropterin help only some patients?

The drug works exclusively in individuals whose PAH gene mutations leave enough functional enzyme intact. Patients with two copies of severe loss-of-function mutations show no response, while responders typically have at least one milder mutation. Genetic testing or a therapeutic trial identifies these responders.

How does sapropterin interact with diet therapy?

Sapropterin can allow patients to increase their phenylalanine intake from food while still maintaining target blood levels. Many patients achieve tighter control or relaxed dietary restrictions, but the drug does not replace a low-phenylalanine diet entirely. Patients still require ongoing blood monitoring.

When does sapropterin receive approval for phenylketonuria?

The FDA approved sapropterin in December 2007 for hyperphenylalaninemia in tetrahydrobiopterin-responsive PKU patients. [1]

What happens if patients stop taking sapropterin?

Blood phenylalanine levels rise rapidly once the drug is discontinued, restoring the ursachen of metabolic decompensation risk. Patients must continue both the drug and diet therapy indefinitely unless clinical data show sustained control after a challenge period.

What patents cover sapropterin?

Patents covering the use of sapropterin for PKU expired or lapsed around 2016–2018, opening the route for generics. Generic versions now compete with the brand Kuvan.